Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.46 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.46 |
| ▸ | CHRNB4 | P30926 | 3/20 | 0.44 |
| ▸ | CHRNA3 | P32297 | 3/20 | 0.44 |
| ▸ | LTA4H | P09960 | 2/20 | 0.43 |
| ▸ | CHRNA5 | P30532 | 1/20 | 0.42 |
| ▸ | PRKCI | P41743 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2017269 | 0.82 | NPSR1 (0.51) | POLBNPSR1 | |
| SCHEMBL2020971 | 0.73 | NPSR1 (0.41) | POLBNPSR1 | |
| SCHEMBL10326450 | 0.72 | LTA4H (0.54) | CHRNA3LTA4H | |
| SCHEMBL10326451 | 0.72 | LTA4H (0.54) | CHRNA3LTA4H | |
| SCHEMBL10326294 | 0.72 | LTA4H (0.54) | CHRNA3LTA4H | |
| SCHEMBL30181400 | 0.70 | CHRNB2 (0.68) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA5 | |
| SCHEMBL29007951 | 0.70 | CHRNB2 (0.68) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA5 | |
| SCHEMBL29007952 | 0.70 | CHRNB2 (0.68) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA5 | |
| SCHEMBL2024209 | 0.69 | CRHR1 (0.41) | NPSR1 | |
| Hydrochloric Acid SCHEMBL30181372 | 0.69 | CHRNB2 (0.67) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8338591-B2 | 3-aryl-5,6-disubstituted pyridazines | NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) | 2012-12-25 | — | — | US | claimed |
| US-8338591-B2 | 3-aryl-5,6-disubstituted pyridazines | NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) | 2012-12-25 | — | — | US | disclosed |
| US-20110160187-A1 | 3-aryl-5,6-disubstituted pyridazines | NEUROGEN CORPORATION (US) | 2011-06-30 | — | — | US | disclosed |
| US-20110160187-A1 | 3-aryl-5,6-disubstituted pyridazines | NEUROGEN CORPORATION (US) | 2011-06-30 | — | — | US | disclosed |
| US-20110160187-A1 | 3-aryl-5,6-disubstituted pyridazines | NEUROGEN CORPORATION (US) | 2011-06-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110160187-A1 | 3-aryl-5,6-disubstituted pyridazines | MMP25, MMP9, MMP3 | POLB 2540/4885NPSR1 1138/4885CHRNB2 4577/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.